{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:50:26Z","timestamp":1790812226382,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs, with which del(1p32) appears to be the second worst abnormality after del(17p). This study aimed to confirm the adverse effect of 1p32 deletion in patients with newly diagnosed multiple myeloma (NDMM). Among 2551 patients with newly diagnosed multiple myeloma, 11% were harboring del(1p32). Their overall survival (OS) was significantly inferior compared with patients without del(1p32) (median OS: 49 months vs 124 months). Likewise, progression-free survival was significantly shorter. More importantly, biallelic del(1p32) conferred a dramatically poorer prognosis than a monoallelic del(1p32) (median OS: 25 months vs 60 months). As expected, the OS of patients with del(1p32) significantly decreased when this abnormality was associated with other high-risk CAs [del(17p), t(4;14), or gain(1q)]. In the multivariate analysis, del(1p32) appeared as a negative prognostic factor; after adjustment for age and treatment, the risk of progression was 1.3 times higher among patients harboring del(1p32), and the risk of death was 1.9 times higher. At the dawn of risk-adapted treatment strategies, we have confirmed the adverse effect of del(1p32) in multiple myeloma and the relevance of its assessment at diagnosis.<\/jats:p>","DOI":"10.1182\/blood.2022017863","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:05:23Z","timestamp":1668441923000},"page":"1308-1315","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor"],"prefix":"10.1182","volume":"141","author":[{"given":"Ana\u00efs","family":"Schavgoulidze","sequence":"first","affiliation":[{"name":"1Unit for Genomics in Myeloma, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse University, INSERM UMR1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6734-413X","authenticated-orcid":false,"given":"Alexis","family":"Talbot","sequence":"additional","affiliation":[{"name":"2Hematology Department, Saint-Louis University Hospital, University of Paris, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"3Hematology Department, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titouan","family":"Cazaubiel","sequence":"additional","affiliation":[{"name":"4Hematology Department, Bordeaux University Hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"5Hematology Department, Poitiers University Hospital, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"6Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-4781","authenticated-orcid":false,"given":"Laure","family":"Buisson","sequence":"additional","affiliation":[{"name":"1Unit for Genomics in Myeloma, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse University, INSERM UMR1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Mah\u00e9o","sequence":"additional","affiliation":[{"name":"1Unit for Genomics in Myeloma, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse University, INSERM UMR1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Do Souto Ferreira","sequence":"additional","affiliation":[{"name":"1Unit for Genomics in Myeloma, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse University, INSERM UMR1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Pavageau","sequence":"additional","affiliation":[{"name":"1Unit for Genomics in Myeloma, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse University, INSERM UMR1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"4Hematology Department, Bordeaux University Hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Marolleau","sequence":"additional","affiliation":[{"name":"7Hematology Department, Amiens University Hospital, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Voillat","sequence":"additional","affiliation":[{"name":"8Hematology Department, Chalon-sur-Sa\u00f4ne Hospital, Chalon-sur-Sa\u00f4ne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj","sequence":"additional","affiliation":[{"name":"9Hematology Department, Cr\u00e9teil University Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5946-311X","authenticated-orcid":false,"given":"Marion","family":"Divoux","sequence":"additional","affiliation":[{"name":"10Hematology Department, Nancy University Hospital, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borhane","family":"Slama","sequence":"additional","affiliation":[{"name":"11Hematology Department, Avignon Hospital, Avignon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Brechignac","sequence":"additional","affiliation":[{"name":"12Hematology Department, Bobigny University Hospital, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"13Hematology Department, Caen University Hospital, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Stoppa","sequence":"additional","affiliation":[{"name":"14Hematology Department, Institut Paoli Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Sanhes","sequence":"additional","affiliation":[{"name":"15Hematology Department, Perpignan Hospital, Perpignan, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Orsini-Piocelle","sequence":"additional","affiliation":[{"name":"16Hematology Department, Annecy Hospital, Annecy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Fontan","sequence":"additional","affiliation":[{"name":"17Hematology Department, Besan\u00e7on University Hospital, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Lorraine","family":"Chretien","sequence":"additional","affiliation":[{"name":"18Hematology Department, Dijon University Hospital, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Demarquette","sequence":"additional","affiliation":[{"name":"19Hematology Department, Dunkerque Hospital, Dunkerque, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"20Hematology Department, Saint-Antoine University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-0140","authenticated-orcid":false,"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"1Unit for Genomics in Myeloma, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse University, INSERM UMR1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"1Unit for Genomics in Myeloma, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse University, INSERM UMR1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2023103115011696100_bib1","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","article-title":"Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods","volume":"35","author":"Corre","year":"2021","journal-title":"Leukemia"},{"issue":"26","key":"2023103115011696100_bib2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023103115011696100_bib3","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2014-07-587964","article-title":"Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience","volume":"125","author":"Hebraud","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023103115011696100_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2013.225","article-title":"Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients","volume":"28","author":"Hebraud","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2023103115011696100_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11684-019-0712-x","article-title":"Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China","volume":"14","author":"Wang","year":"2020","journal-title":"Front Med"},{"issue":"19","key":"2023103115011696100_bib6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2023103115011696100_bib7","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2023103115011696100_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2023103115011696100_bib9","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"2023103115011696100_bib10","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2023103115011696100_bib11","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1038\/bcj.2016.72","article-title":"A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma","volume":"6","author":"Bolli","year":"2016","journal-title":"Blood Cancer J"},{"issue":"33","key":"2023103115011696100_bib12","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023103115011696100_bib13","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/s41598-020-62885-0","article-title":"Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance","volume":"10","author":"Baysal","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"2023103115011696100_bib14","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2023103115011696100_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A\u00a0high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"2023103115011696100_bib16","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.280566","article-title":"Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma","author":"Schavgoulidze","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"2023103115011696100_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2016.03.006","article-title":"Cytogenetics and survival of multiple myeloma: isolated and combined effects","volume":"16","author":"Sergentanis","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"29","key":"2023103115011696100_bib18","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) Report within the HARMONY Project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"2023103115011696100_bib19","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S2152-2650(21)02126-1","article-title":"OAB-052: impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial","volume":"21","author":"Kapoor","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2023103115011696100_bib20","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2643-3230.BCD-21-0205","article-title":"Perspectives on the risk-stratified treatment of multiple myeloma","volume":"3","author":"Davies","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"2023103115011696100_bib21","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2019001425","article-title":"Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents","volume":"4","author":"Giri","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2023103115011696100_bib22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/11\/1308\/2086568\/blood_bld-2022-017863-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/11\/1308\/2086568\/blood_bld-2022-017863-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:02:02Z","timestamp":1698750122000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/11\/1308\/487111\/Biallelic-deletion-of-1p32-defines-ultra-high-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,3,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017863","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}